A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N
A phase 2 trial of PM8002, Paclitaxel / nab-paclitaxel, Gemcitabine in pancreatic ductal adenocarcinoma, run by BioNTech SE, now recruiting.
Overview
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer is a phase 2 interventional study registered as NCT07255404 by BioNTech SE, with 105 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12. Interventions recorded: Pumitamig, Nab-paclitaxel, Gemcitabine, mFOLFIRINOX. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Shares FOLFIRINOX / mFOLFIRINOX, Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialPM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- TrialA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
- TrialPM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC